Cargando…

Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts

Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by progressive cognitive decline. The two cardinal neuropathological hallmarks of AD include the buildup of cerebral β amyloid (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau. The current disease-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Awasthi, Shivangi, Spellman, Daniel S., Hatcher, Nathan G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397030/ https://www.ncbi.nlm.nih.gov/pubmed/35997438 http://dx.doi.org/10.3390/proteomes10030026

Ejemplares similares

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort
por: Westwood, Sarah, et al.
Publicado: (2020)

Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
por: Bai, Bing, et al.
Publicado: (2021)

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
por: Bader, Jakob M, et al.
Publicado: (2020)

Biomarker discovery in human cerebrospinal fluid: the need for integrative metabolome and proteome databases
por: Schwarz, Emanuel, et al.
Publicado: (2012)

Correction to: Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
por: Bai, Bing, et al.
Publicado: (2021)

Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer’s disease biomarkers
por: van Zalm, Patrick W., et al.
Publicado: (2023)

Advancement of Biomarker Discovery and Validation through the HUPO Plasma Proteome Project
por: Omenn, Gilbert S.
Publicado: (2004)

An Integrated Quantitative Proteomics Workflow for Cancer Biomarker Discovery and Validation in Plasma
por: Kumar, Vipin, et al.
Publicado: (2020)

The iterative process of fluid biomarker development and validation in Alzheimer's disease
por: Bendlin, Barbara B., et al.
Publicado: (2022)

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
por: Wildsmith, Kristin R, et al.
Publicado: (2014)

In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery
por: Zhang, Jian, et al.
Publicado: (2017)

The amniotic fluid proteome changes with term labor and informs biomarker discovery in maternal plasma
por: Bhatti, Gaurav, et al.
Publicado: (2023)

Proteomics Discovery of Disease Biomarkers
por: Ahram, Mamoun, et al.
Publicado: (2008)

Shotgun Proteomics and Biomarker Discovery
por: McDonald, W. Hayes, et al.
Publicado: (2002)

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid
por: Hendrickson, Ronald C., et al.
Publicado: (2015)

Discovery and Validation of Key Biomarkers Based on Immune Infiltrates in Alzheimer’s Disease
por: Liu, Zhuohang, et al.
Publicado: (2021)

Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer’s disease
por: Dey, Kaushik Kumar, et al.
Publicado: (2019)

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
por: Zhong, Xiaofang, et al.
Publicado: (2019)

Dataset describing the development, optimization and application of SRM/MRM based targeted proteomics strategy for quantification of potential biomarkers of EGFR TKI sensitivity
por: Awasthi, Shivangi, et al.
Publicado: (2018)

Autoantibody Profiling on Human Proteome Microarray for Biomarker Discovery in Cerebrospinal Fluid and Sera of Neuropsychiatric Lupus
por: Hu, Chaojun, et al.
Publicado: (2015)

Identification of Candidate Biomarkers of Alzheimer’s Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics
por: Liu, Ping, et al.
Publicado: (2023)

Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation
por: Greco, Ines, et al.
Publicado: (2012)

Feature Selection Methods for Protein Biomarker Discovery from Proteomics or Multiomics Data
por: Shi, Zhiao, et al.
Publicado: (2021)

Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis
por: Núñez, Estefanía, et al.
Publicado: (2022)

Proteomic and metabolomic approaches to biomarker discovery
por: Issaq, Haleem J, et al.
Publicado: (2019)

Proteomics as a Tool for Biomarker Discovery
por: Kohn, Elise C., et al.
Publicado: (2007)

Discovery of Biomarkers for Osteosarcoma by Proteomics Approaches
por: Suehara, Yoshiyuki, et al.
Publicado: (2012)

Revisiting biomarker discovery by plasma proteomics
por: Geyer, Philipp E, et al.
Publicado: (2017)

Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients
por: Bai, Shumei, et al.
Publicado: (2009)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
por: Shi, Liu, et al.
Publicado: (2019)

Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation
por: Perrin, Richard J., et al.
Publicado: (2013)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluid
por: Winchester, Laura, et al.
Publicado: (2022)

Ensemble feature selection with data-driven thresholding for Alzheimer's disease biomarker discovery
por: Spooner, Annette, et al.
Publicado: (2023)

Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease
por: Perrin, Richard J., et al.
Publicado: (2011)

Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease
por: Higginbotham, Lenora, et al.
Publicado: (2020)

Proteome Profiling of Diabetic Mellitus Patient Urine for Discovery of Biomarkers by Comprehensive MS-Based Proteomics
por: Hirao, Yoshitoshi, et al.
Publicado: (2018)

Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
por: Libiger, Ondrej, et al.
Publicado: (2021)

Bench to Bedside: Proteomic Biomarker Analysis of Cerebrospinal Fluid in Patients With Spondylomyelopathy
por: Fiani, Brian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_18s7q0kiohhvac08vt6o7buat2